Litcius/Paper detail

Chrysin 7-O-β-D-glucuronide, a dual inhibitor of SARS-CoV-2 3CLpro and PLpro, for the prevention and treatment of COVID-19

Yi Yang, Rong Yu, Heng Xue, Zhengtong Jin, Meng Zhang, Yang‐Oujie Bao, Zilong Wang, Hongping Wei, Xue Qiao, Hang Yang

2023International Journal of Antimicrobial Agents15 citationsDOIOpen Access PDF

Abstract

The evolution of SARS-CoV-2 virus has resulted in the global pandemic COVID-19. Given the advent of subvariants, it is urgent to develop novel drugs. This work aims to discover SARS-CoV-2 inhibitors from Scutellaria baicalensis Georgi targeting the proteases 3CLpro and PLpro. After screening 25 flavonoids, we revealed that chrysin 7-O-β-D-glucuronide could potently inhibit SARS-CoV-2 on Vero E6 cells, with EC50 of 8.72 μM. Surface plasmon resonance, site-directed mutagenesis and enzymatic activity measurements indicated chrysin-7-O-β-D-glucuronide inhibits SARS-CoV-2 through binding to H41 of 3CLpro, and K157 and E167 of PLpro, and hydrogen-deuterium exchange mass spectrometry analysis showed PLpro conformation has remarkable changes caused by chrysin-7-O-β-D-glucuronide. Finally, we revealed anti-inflammatory activity of chrysin 7-O-β-D-glucuronide mainly caused by decreasing level of proinflammatory cytokines IL-1β and IL-6.

Topics & Concepts

ChrysinChemistryScutellaria baicalensisPharmacologyProinflammatory cytokineBiochemistryBiologyInflammationFlavonoidMedicineImmunologyPathologyTraditional Chinese medicineAntioxidantAlternative medicineFlavonoids in Medical ResearchPlant-based Medicinal ResearchComputational Drug Discovery Methods
Chrysin 7-O-β-D-glucuronide, a dual inhibitor of SARS-CoV-2 3CLpro and PLpro, for the prevention and treatment of COVID-19 | Litcius